Image Description

INVESTORS
& MEDIA

circle

Cytokinetics in the News

Here you can find the latest articles about Cytokinetics, along with fact sheets describing the company, our clinical programs and background on our areas of disease focus – ALS, heart failure and SMA.
DateTitle 
March 23, 2017, SMA News TodayCytokinetics' CK-2127107 Improves Muscle Function in Mice with SMA, Study Shows
February 3, 2017, BioWorld $100M positions Cytokinetics well re Amgen with omecamtiv
February 2, 2017, BioCenturyCytokinetics strikes royalty deal for omecamtiv mecarbil
February 2, 2017, XconomyRoyalty Pharma Pays $90M to Cytokinetics for Heart Drug Royalties
February 2, 2017, BioPharma DiveCytokinetics pulls in Royalty Pharma to secure $100M
February 2, 2017, First Word PharmaViewPoints: Cytokinetics, Amgen have long believed omecamtiv mecarbil is a blockbuster in waiting - Royalty Pharma clearly agrees
December 12, 2016, ALS News TodayCytokinetics Presents New Data at 27th International Symposium on ALS/MND
December 5, 2016, Cardiovascular BusinessOral heart failure medication proves safe, effective in phase 2 trial
October 13, 2016, Harvard Business SchoolAdding Muscle to the Fight Against Disease
September 2, 2016, BioWorldAmgen to carry Cytokinetics HF drug into phase III
August 23, 2016, EP VantageInterview – Cytokinetics muscles up in Lou Gehrig's disease
August 23, 2016, ALS News Today Cytokinetics Enrolls 700 ALS Patients in Phase 3 Study of Tirasemtiv
August 19, 2016, The Pink SheetCytokinetics Seeks ALS Success By Focusing On Lung Function
July 28, 2016, ALS News TodayCytokinetics and ALS Association Expand Efforts to Improve ALS Treatment and Care
July 28, 2016, BioWorldExpanded Astellas deal to advance Cytokinetics muscle biology in ALS
July 27, 2016, EndpointsEyeing a potential market launch, Astellas orders up a $95M third course of Cytokinetics' pipeline
July 27, 2016, FierceBiotechAstellas boosts funding, involvement in updated Cytokinetics collab
July 27, 2016, KCBS SF Bay AreaMajor Funding For New Drugs To Help People Suffering From ALS
July 27, 2016, Xconomy Cytokinetics Gets $95M in First ALS Deal, Needs Results For More
July 5, 2016, COPD News TodayCytokinetics Begins Phase 2 Study of Therapy for COPD Patients
June 2, 2016, Cardiology Today COSMIC-HF: Omecamtiv mecarbil shows promise for favorable ventricular remodeling
March 1, 2016, ALS News Today ALS Drug Developer Cytokinetics Joins Rare Disease Day Efforts to Educate and Promote Change

Cytokinetics Fact Sheets